A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

NCT04200248 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Exudative Age-related Macular Degeneration

Interventions

DRUG: RBM-007 Injectable Solution
DRUG: Aflibercept
DRUG: Sham

Sponsor

Ribomic USA Inc